Just a moment, the page is loading...
The GSK Supported Studies Portal is being upgraded and will be unavailable from Wednesday 27th of January at 5.00PM EST to Tuesday 2nd of February 7.00am EST . If you are anticipating submitting a proposal during this time please submit once the new system is live on the 2nd of February. During this time please contact your Country Medical Point of Contact for any queries. We apologise for any inconvenience.
The Supported Studies Programme
For the latest updates on GSK’s response to COVID-19, please click here.

Classic & Established (Marketed)



Timelines





The following areas are of particular interest to the review committee. These were last updated in January 2020.

[Allergy]
• Understand burden of Allergic Rhinitis
• Allergic Rhinitis- Diagnosis and management
• Fluticasone Furoate nasal spray in Allergic Rhinitis management
• Role of sensory attributes in the management of Allergic Rhinitis- Use of intranasal corticosteroids
• Levocetirizine in management of Allergic Rhinitis and Urticaria
• Link between Allergic Rhinitis and Asthma- Impact of appropriate Allergic Rhinitis management on Asthma control


[Dermatology]
• Steroid-responsive dermatoses: Appropriate use of topical corticosteroids
• Androgenetic alopecia: Sexual dysfunction associated with 5ARI/alpha blocker therapy as a barrier to optimal treatment management in androgenetic alopecia
• Androgenetic alopecia: post hair-transplant treatment with dutasteride/5ARIs (Alpha Reductase Inhibitors)
• Acne: antibiotic resistance with antibiotic-containing fixed-dose combinations

[Urology]
Research proposals addressing barriers to optimal treatment management including exploration of real world clinical practice data and patient outcomes:
• 5ARI/alpha blocker combination vs alpha blocker monotherapy in BPH treatment paradigm - pros and cons of differential therapeutic approaches in moderate to severe LUTS/BPH
• Evaluation, management and monitoring of Lower urinary tract symptoms/ benign prostatic hypertrophy (LUTS/BPH) in driving optimal treatment outcomes in benign prostatic hypertrophy benign prostatic hypertrophy (BPH) patients
• Sexual dysfunction associated with 5ARI/alpha blocker therapy as a barrier to optimal treatment management in benign prostatic hypertrophy (BPH)
• Understanding risk of progression in benign prostatic hypertrophy (BPH) patients - role of urodynamic and mechanistic aspects

[Infectious Diseases]
• Proposals supporting appropriate antibiotic prescribing (dose, duration, PK/ PD- pharmacokinetic/ pharmacodyn principles),
• Antibiotic stewardship,
• Strategies to minimise development of antimicrobial resistance in the community

[Respiratory]
(Products: Salmeterol plus fluticasone, fluticasone and salbutamol, fluticasone furoate plus vilanterol)

Epidemiology, disease progression parameters and asthma management :
•   What are the parameters indicating asthma disease progression (mild to moderate and beyond)?
•   Studies that helps in characterisation of patients that progress vs those that do not progress
•   Effectiveness of Regular ICS + SABA (Inhaled corticosteroid +short acting beta agonists) prn in asthma control and reducing the risk of exacerbation – In adults and paediatric population
•   Exploring patient behaviour in relation to adherence in asthma

Medicines (including comparators) e.g.
•   Effectiveness of ICS/LABA therapy in moderate-severe asthma
•   Using registries or databases to track patients’ journey through the health system to look at differences between ICS/ICS+SABA and other treatment regimens in asthma (including paediatrics and adults asthma)
•   Innovative studies or models, to track patients’ disease progression journey when initiated on various treatments in mild asthma (SABA, mono ICS or ICS/LABA as required)
•   Studies to characterise inflammatory profile/phenotype of asthma exacerbations/cluster analysis to identify endotypes or phenotypes of patients that exacerbate
•   Studies looking at longitudinal trajectory of airway inflammation in mild asthma using inflammatory markers (example- blood/sputum eosinophils FeNO

Adherence/ patient support programme
•   Studies linking improved adherence with improved outcomes in paediatric / adult asthma patients e.g. Interventions with Apps and other tools.
•   Studies to understand patient behaviours around non-adherence


Although GSK are more likely to support studies aligned to our current areas of interest for supported studies, we are interested in supporting studies that are innovative and contribute to scientific knowledge relating to a product, a medical condition or advancing a technology.



© 2001-2021 GlaxoSmithKline plc. All rights reserved. Registered in England and Wales No. 3888792.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.